MISSION VIEJO, CA--(Marketwire - March 13, 2012) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS: AOLS), a biotechnology company leveraging significant government funding to develop a platform of novel compounds in oncology and biodefense, today announced that it will be presenting at Roth Capital Partners' 24th Annual Growth Stock Conference at the Ritz Carlton Hotel in Dana Point, CA. John McManus, the Company's Chief Executive Officer, will be presenting a corporate update, including an update on Aeolus' contract with the Biomedical Advanced Research and Development Authority (BARDA), with options valued at $118 million. The company will discuss progress and results during the first twelve months of the contract, as well as the components of the potential upcoming options that are available to be exercised by BARDA.
The presentation is scheduled for Wednesday, March 14, at 11:30 a.m. PT. The presentation will be webcast and will be available through the investor relations section of the Company's website at www.aeoluspharma.com.
The statements in this press release that are not purely statements of historical fact are forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Aeolus' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Certain of these factors and others are more fully described in Aeolus' filings with the Securities and Exchange Commission, including, but not limited to, Aeolus' amended Annual Report on Form 10-K/A for the year ended September 30, 2010. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.